Microsatellite instability and therapeutic consequences in colorectal cancer

Digestive Diseases

Volumn 30, Issue 3, 2012, Pages 304-309

  Laghi, Luigi ^a,b   Malesci, Alberto ^b,c  

^a Molecular Gastroenterology Unit   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Colorectal cancer; Hereditary nonpolyposis colorectal cancer; Microsatellite instability

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH3; PROTEIN MSH6;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; DISEASE SPECIFIC SURVIVAL; DNA METHYLATION; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; TREATMENT RESPONSE;

COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; HUMANS; MICROSATELLITE INSTABILITY; PROGNOSIS; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84862889606     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000337003     Document Type: Article

References (21)

1. Markowitz SD, Bertagnolli MM: Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-2460.
2. NCBI: Online Mendelian Inheritance in Man (OMIM). 2007. http://www.ncbi.nlm. nih.gov/sites/entrez?db=OMIM.
3. Laghi L, Bianchi P, Malesci A: Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene 2008; 27: 6313-6321.
4. Laghi L, Ranzani GN, Bianchi P, et al: Frameshift mutations of human gastrin receptor gene (hGARE) in gastrointestinal cancers with microsatellite instability. Lab Invest 2002; 82: 265-271. (Pubitemid 34242520)
5. Thibodeau SN, French AJ, Roche PC, et al: Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 1996; 56: 4836-4840. (Pubitemid 26374414)
6. Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257. (Pubitemid 28521189)
7. Aaltonen LA, Salovaara R, Kristo P, et al: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 338: 1481-1487. (Pubitemid 28226275)
8. Mvundura M, Grosse SD, Hampel H, Palomaki GE: The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010; 12: 93-104.
9. Laghi L, Bianchi P, Miranda E, et al: CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: A longitudinal study. Lancet Oncol 2009; 10: 877-884.
10. Lindor NM, Rabe K, Petersen GM, et al: Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005; 293: 1979-1985. (Pubitemid 40570891)
11. Malesci A, Laghi L, Bianchi P, et al: Reduced likelihood of metastases in patients with microsatellite- unstable colorectal cancer. Clin Cancer Res 2007; 13: 3831-3839. (Pubitemid 47037588)
12. Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E: Microsatellite instability as a marker of prognosis and response to therapy: A meta-Analysis of colorectal cancer survival data. Eur J Cancer 2010; 46: 2788-2798.
13. Gryfe R, Kim H, Hsieh ET, et al: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69-77. (Pubitemid 30036597)
14. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257. (Pubitemid 36859476)
15. Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-3226.
16. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B: Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-Analysis. Eur J Cancer 2009; 45: 1890-1896.
17. Sinicrope FA, Foster NR, Thibodeau SN, et al: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103: 863-875.
18. Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al: Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 2010; 21: 772-780.
19. Bertagnolli MM, Niedzwiecki D, Compton CC, et al: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009; 27: 1814-1821.
20. Vasen HF, Watson P, Mecklin JP, Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999; 116: 1453-1456. (Pubitemid 29258894)
21. Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268. (Pubitemid 38256271)